OPKO Health, Inc. Treasury Stock Acquired, Average Cost Per Share
OPKO Health, Inc. (OPK) reported Treasury Stock Acquired, Average Cost Per Share of $1.39 per share for the 6-month period ending 2026-06-30, per its 10-Q/A filed 2026-08-28.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:TreasuryStockAcquiredAverageCostPerShare · last filed 2026-08-28
- OPKO Health, Inc. treasury stock acquired, average cost per share for the quarter ending 2026-03-31 was $1.21.
- OPKO Health, Inc. treasury stock acquired, average cost per share for fiscal 2025 was $1.36, a 12.82% decline from fiscal 2024.
- OPKO Health, Inc. treasury stock acquired, average cost per share for fiscal 2024 was $1.56.
| Period end | Treasury Stock Acquired, Average Cost Per Share | Treasury Stock Acquired, Average Cost Per Share 3 month | Treasury Stock Acquired, Average Cost Per Share 6 month | Treasury Stock Acquired, Average Cost Per Share 12 month |
|---|---|---|---|---|
| 2026-06-30 | $1.39 10-Q/A · filed 2026-08-28 | |||
| 2026-03-31 | $1.21 10-Q/A · filed 2026-08-28 | |||
| 2025-12-31 | $1.36 10-K · filed 2026-02-26 | |||
| 2024-12-31 | $1.56 10-K · filed 2026-02-26 | |||
| 2024-07-18 | $1.56 10-K · filed 2025-03-03 | |||
| 2024-01-09 | $0.91 10-Q/A · filed 2026-08-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| HARROW, INC. (HROW) | United States | $1.240B | -42.77 |
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| Jaguar Health, Inc. (JAGX) | United States | $1.184B | |
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |